JGC
MREO

J. Goldman & Co’s Mereo BioPharma MREO Stock Holding History

J. Goldman & Co’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,400
Closed -$36.4K – 565
2024
Q4 		$36.4K Buy
+10,400
New +$40.9K ﹤0.01% 429
2022
Q3 		– Sell
-75,000
Closed -$84K – 443
2022
Q2 		$84K Buy
+75,000
New +$58.1K ﹤0.01% 323

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's MREO Position: Q3 2025 in Review

J. Goldman & Co sold out of Mereo BioPharma (MREO) in Q3 2025, closing a stake of 52,384 shares — an estimated $142K sold.

J. Goldman & Co first reported a position in MREO in Q3 2020 and held it in 20 quarters. The position peaked at $1.99M in Q2 2021. 84 funds tracked by Wall St. Rank hold MREO as of Q3 2025.

  • J. Goldman & Co reported no remaining Mereo BioPharma position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 52,384 Mereo BioPharma shares in Q3 2025, an estimated $142K.
  • J. Goldman & Co first reported a position in Mereo BioPharma in Q3 2020 and held it in 20 quarters.
  • J. Goldman & Co's Mereo BioPharma position peaked at $1.99M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.